# A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Study · id `cardio:ct-nct05144984` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05144984](<https://clinicaltrials.gov/study/NCT05144984>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05144984

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

## Technical summary

Registry record NCT05144984. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-29 (actual); primary completion 2023-02-13 (actual). Results posted on 2026-04-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 500 participants (enrolled count; ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Started: 2021-11-29 (actual) (ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Primary completion: 2023-02-13 (actual) (ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Completion: 2023-03-23 (actual) (ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Results first posted: 2026-04-09 (ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Denmark; Greece; Hungary; Japan; Poland; Russia; Serbia (ClinicalTrials.gov record NCT05144984, source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05144984-2026-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): NNC0480-0389
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (NNC080-0389)
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 47335105e87fe537bc7ef8585d1ba47aae8ecbcceadbb3d0c11dd5aacd471f81
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
